Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency
NCT06120972
·
clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
OTHER
Sponsor class
Stopped
Sponsor terminated due to Olaparib losing patent
Conditions
Ovarian Cancer
Interventions
DRUG:
Olaparib tablet
Sponsor
Alexander B Olawaiye, MD
Collaborators
[object Object]